Skip to Content

Benzonatate

Dosage Form: capsule

Benzonatate Description

Benzonatate capsules  USP a non-narcotic oral antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaoctacosan-28-yl p-(butylamino) benzoate; with a molecular weight of 603.7.

structure

Each Benzonatate capsule USP, 100 mg contains:

Benzonatate USP 100 mg

Each Benzonatate capsule USP, 200 mg contains:

Benzonatate USP 200 mg

Benzonatate capsules USP also contain: D&C Yellow 10, gelatin, glycerin, methylparaben and propylparaben.

Ingredients of the imprinting ink are: Propylene glycol, shellac resins, sodium lauryl sulphate, isopropyl alcohol and titanium dioxide.

Benzonatate - Clinical Pharmacology

Benzonatate acts peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs, and pleura by dampening their activity and thereby reducing the cough reflex at its source. It begins to act within 15 to 20 minutes and its effect lasts for 3 to 8 hours. Benzonatate has no inhibitory effect on the respiratory center in recommended dosage.

Indications and Usage for Benzonatate

Benzonatate capsules USP are indicated for the symptomatic relief of cough.

Contraindications

Hypersensitivity to Benzonatate or related compounds.

Warnings

Hypersensitivity

Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. Severe reactions have required intervention with vasopressor agents and supportive measures.

Psychiatric Effects

Isolated instances of bizarre behavior, including mental confusion and visual hallucinations, have also been reported in patients taking Benzonatate in combination with other prescribed drugs.

Accidental Ingestion and Death in Children

Keep Benzonatate out of reach of children. Accidental ingestion of Benzonatate resulting in death has been reported in children below age 10. Signs and symptoms of overdose have been reported within 15 to 20 minutes and death has been reported within one hour of ingestion. If accidental ingestion occurs, seek medical attention immediately (see OVERDOSAGE).

Precautions

Benzonatate is chemically related to anesthetic agents of the para-aminobenzoic acid class (e.g. procaine; tetracaine) and has been associated with adverse CNS effects possibly related to prior sensitivity to related agents or interaction with concomitant medication.

Information for patients:

Swallow Benzonatate capsules whole. Do not break, chew, dissolve, cut, or crush Benzonatate capsules. Release of Benzonatate from the capsule in the mouth can produce a temporary local anesthesia of the oral mucosa and choking could occur. If numbness or tingling of the tongue, mouth, throat, or face occurs, refrain from oral ingestion of food or liquids until the numbness has resolved. If the symptoms worsen or persist, seek medical attention.

Keep Benzonatate out of reach of children. Accidental ingestion resulting in death has been reported in children. Signs and symptoms of overdose have been reported within 15 to 20 minutes and death has been reported within one hour of ingestion. Signs and symptoms may include restlessness, tremors, convulsions, coma and cardiac arrest. If accidental ingestion occurs, seek medical attention immediately.

Overdosage resulting in death may occur in adults.

Do not exceed a single dose of 200 mg and a total daily dosage of 600 mg. If you miss a dose of Benzonatate, skip that dose and take the next dose at the next scheduled time. Do not take 2 doses of Benzonatate at one time.

Usage in Pregnancy

Pregnancy Category C. Animal reproduction studies have not been conducted with Benzonatate. It is also not known whether Benzonatate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Benzonatate should be given to a pregnant woman only if clearly needed.

Nursing mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk caution should be exercised when Benzonatate is administered to a nursing woman.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity, mutagenicity, and reproduction studies have not been conducted with Benzonatate.

Pediatric Use

Safety and effectiveness in children below the age of 10 have not been established. Accidental ingestion resulting in death has been reported in children below age 10. Keep out of reach of children.

Adverse Reactions

Potential Adverse Reactions to Benzonatate may include:

Hypersensitivity reactions

including bronchospasm, laryngospasm, cardiovascular collapse possibly related to local anesthesia from chewing or sucking the capsule.

CNS

Sedation; headache; dizziness; mental confusion; visual hallucinations.

GI

Constipation; nausea; GI upset.

Dermatologic

Pruritus; skin eruptions.

Other

Nasal congestion; sensation of burning in the eyes; vague "chilly" sensation; numbness of the chest; hypersensitivity.

Deliberate or accidental overdose has resulted in death, particularly in children.

Overdosage

Intentional and unintentional overdose may result in death, particularly in children.

The drug is chemically related to tetracaine and other topical anesthetics and shares various aspects of their pharmacology and toxicology. Drugs of this type are generally well absorbed after ingestion.

Signs and Symptoms

The signs and symptoms of overdose of Benzonatate have been reported within 15-20 minutes. If capsules are chewed or dissolved in the mouth, oropharyngeal anesthesia will develop rapidly, which may cause choking and airway compromise.

CNS stimulation may cause restlessness and tremors which may proceed to clonic convulsions followed by profound CNS depression. Convulsions, coma, cerebral edema and cardiac arrest leading to death have been reported within 1 hour of ingestion.

Treatment:

In case of overdose, seek medical attention immediately. Evacuate gastric contents and administer copious amounts of activated charcoal slurry. Even in the conscious patient, cough and gag reflexes may be so depressed as to necessitate special attention to protection against aspiration of gastric contents and orally administered materials. Convulsions should be treated with a short-acting barbiturate given intravenously and carefully titrated for the smallest effective dosage. Intensive support of respiration and cardiovascular-renal function is an essential feature of the treatment of severe intoxication from overdosage.

Do not use CNS stimulants.

Benzonatate Dosage and Administration

Adults and Children over 10 years of age: Usual dose is one 100 mg or 200 mg capsule three times a day as needed for cough. If necessary to control cough, up to 600 mg daily in three divided doses may be given. Benzonatate capsules USP should be swallowed whole. Benzonatate capsules USP are not to be broken, chewed, dissolved, cut or crushed.

How is Benzonatate Supplied

Benzonatate capsules USP, 100 mg are available as yellow colored, oval shaped soft gelatin capsules, imprinted as '705' in white ink and containing clear, pale yellow viscous liquid.

NDC 64380-712-06 in bottles of 100 capsules.

Benzonatate capsules USP, 200 mg are available as yellow colored, oval shaped soft gelatin capsules, imprinted as '704' in white ink and containing clear, pale yellow viscous liquid.

NDC 64380-713-06 in bottles of 100 capsules.

Store at 20° to 25°C (68° to 77°F) [See USP controlled room temperature].

Dispense in a tight, light-resistant container.

For more information please contact Strides Arcolab Limited on 1-877-244-9825 or go to www.stridesarco.com

Manufactured by:

Strides Arcolab Limited

Bangalore-560076, India

Distributed by:

Strides Pharma Inc.

201 South Main Street, Suite 3

Lambertville, NJ08530 USA

Rx Only

Revised: 11/2014

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

container-label-100mg

container-label-200mg

Benzonatate 
Benzonatate capsule
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:64380-712
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Benzonatate (Benzonatate) Benzonatate 100 mg
Inactive Ingredients
Ingredient Name Strength
D&C YELLOW NO. 10  
GELATIN  
GLYCERIN  
METHYLPARABEN  
PROPYLPARABEN  
Product Characteristics
Color YELLOW (Yellow) Score no score
Shape OVAL (oval shaped) Size 9mm
Flavor Imprint Code 705
Contains         
Packaging
# Item Code Package Description
1 NDC:64380-712-06 100 CAPSULE in 1 CONTAINER
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA091133 07/30/2015
Benzonatate 
Benzonatate capsule
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:64380-713
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Benzonatate (Benzonatate) Benzonatate 200 mg
Inactive Ingredients
Ingredient Name Strength
METHYLPARABEN  
PROPYLPARABEN  
D&C YELLOW NO. 10  
GLYCERIN  
GELATIN  
Product Characteristics
Color YELLOW (Yellow) Score no score
Shape OVAL (oval shaped) Size 10mm
Flavor Imprint Code 704
Contains         
Packaging
# Item Code Package Description
1 NDC:64380-713-06 100 CAPSULE in 1 CONTAINER
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA091133 07/30/2015
Labeler - Strides Arcolab Limited (650738743)
Revised: 08/2015
 
Strides Arcolab Limited
Hide